Physician profile
Penelope Yanni
NPI 1912944414
$1,655.98
in general payments reported to CMS, 2019-2025
14 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.32 · 2020: $29.99 · 2021: $82.82 · 2022: $638 · 2023: $231 · 2024: $333 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.60 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $242.49 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $98.55 | 2023-2025 | Rexulti, Abilify Mycite |
| Lundbeck LLC | $44.86 | 2022-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $36.50 | 2022 | |
| Allergan, INC. | $29.99 | 2020 | |
| Sage Therapeutics, LLC | $26.85 | 2024 | |
| Alkermes, INC. | $24.81 | 2022 | |
| Neuronetics, INC. | $23.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.93 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $21.46 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $19.37 | 2021 | |
| Corium, LLC | $16.89 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $16.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penelope Yanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.